Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2017 - 2026)
Kiniksa Pharmaceuticals International's (KNSA) quarterly Operating Expenses came in at $216.4 million in Q2 2026, up 58.38% YoY from $136.6 million in Q2 2025, and up 16.98% on a QoQ basis from $185.0 million in Q1 2026.
Kiniksa Pharmaceuticals International (KNSA) Operating Expenses (2017 - 2026) Analysis & Trends
Kiniksa Pharmaceuticals International (KNSA) has 10 years of Operating Expenses data on file, last reported at $216.4 million in Q2 2026.
- Quarterly Operating Expenses rose 58.38% year-over-year to $216.4 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $740.6 million (up 41.1% YoY) and the FY2025 annual result came in at $600.3 million, up 28.04% from the prior year.
- Operating Expenses advanced to $216.4 million in Q2 2026, from $185.0 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $216.4 million in Q2 2026 to a low of $46.3 million in Q2 2022.
- A 5-year average of $109.8 million and a median of $102.6 million in 2024 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2022 — Operating Expenses retreated 3.98% — and 2024, when it jumped 70.24%.
- Tracing KNSA's Operating Expenses over 5 years: stood at $55.8 million in 2022, then jumped by 49.21% to $83.3 million in 2023, then surged by 70.24% to $141.8 million in 2024, then rose by 28.57% to $182.4 million in 2025, then advanced by 18.67% to $216.4 million in 2026.
- The last three Operating Expenses figures came in at $216.4 million (Q2 2026), $185.0 million (Q1 2026), and $182.4 million (Q4 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 1.29 Bn |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 215.00 Mn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | -2.85 Bn |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 452.50 Mn |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 1.45 Bn |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 807.50 Mn |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 550.00 Mn |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Kiniksa Pharmaceuticals International | 6.08 Bn | 5.55 Bn | 220.03 Mn | 216.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 216.41 Mn |
| Mar 31, 2026 | 185.00 Mn |
| Dec 31, 2025 | 182.36 Mn |
| Sep 30, 2025 | 156.83 Mn |
| Jun 30, 2025 | 136.64 Mn |
| Mar 31, 2025 | 124.51 Mn |
| Dec 31, 2024 | 141.84 Mn |
| Sep 30, 2024 | 121.87 Mn |
| Jun 30, 2024 | 108.75 Mn |
| Mar 31, 2024 | 96.40 Mn |
| Dec 31, 2023 | 83.31 Mn |
| Sep 30, 2023 | 77.97 Mn |
| Jun 30, 2023 | 74.63 Mn |
| Mar 31, 2023 | 59.54 Mn |
| Dec 31, 2022 | 55.84 Mn |
| Sep 30, 2022 | 52.72 Mn |
| Jun 30, 2022 | 46.34 Mn |
| Mar 31, 2022 | 55.51 Mn |
| Dec 31, 2021 | 54.88 Mn |
| Sep 30, 2021 | 42.76 Mn |